The Most Recommended Pharma and Life Science Solution Provider In 2021

™

™

The Most Recommended Pharma and Life Sciences Solution Providers in 2020

T

he Pharma and Life Sciences industry has always been driven by great innova on and research in the drug development. In these challenging mes, it has been pushed more than ever. Because the industry has come up with promising and good quality drugs that have had an immense impact in recovery rates, there have been massive investments to back these innova ons.

This issue of The Business Fame of The Most Recommended Pharma and Life Sciences Solu on Providers in 2020 features some of the best companies that have provided the world with their innova ve solu ons and given a new turn to healthcare.

Featuring for the Cover Story is OnShore Technology Group, a Chicago-based firm specializing in life sciences, has developed lean valida on; an op mized valida on process. It is designed to help eliminate waste and inefficiencies tradi onally found in manual valida on processes while streamlining and integra ng quality and value to your company. This innova ve methodology will ul mately conserve your resources enabling more cri cal thinking and facilita ng more rigorous tes ng and so ware assurance.

Started in the year 2004, Scube Scien fic is an ISO 9001:2015 cer fied renowned distributor of some of the leading edge, easy to use and affordable scien fic so ware tools pan India and also to the neighboring

SAARC countries. Their services cater for assis ng the research scien sts with tools that help them in their daily scien fic ac vi es. Their marke ng and technical support team work together with the clients to offer tailor-made solu ons for their scien fic so ware needs.

An bio c resistance is on the rise. The healthcare industry is now in need of new an bio cs and therapies to treat infec ous diseases and viruses. This is where pres gious companies like Interna onal Health Management Associates or IHMA enters. The company is working with pharmaceu cal companies to develop new an bio cs and therapies for infec ous diseases. They are also working with diagnos c companies in order to test these new an bio cs.

Techsol Corpora on was founded in 2010 under the leadership of Satya S. S Sagi, CEO with his vision for offering value-based technology services and developing innova ve so ware solu ons for pharma. With over 20 years of life sciences industry experience, the humble beginnings of Techsol were started by him on a small penthouse overseeing Hi-Tec city in Hyderabad, India.

Today with our headquarters in Princeton, NJ, we are recognized as a valuable tech partner for several global clients with an expanded team of 140+ subject ma er experts.

™

ISO 9001:2015 Certied Media Firm

COVER STORY

ONSHORE TECHNOLOGY GROUP

08

A 16 Year Legacy Empowering Life Science Businesses with Automation

BEST OF PHARMA AND LIFE SCIENCE

16 20 24

Scube Scientific Software Solutions Pvt. Ltd.

Innovative and Affordable Scientific Software Solutions

International Health Management Associates Redefining the Drug Discovery Process with Unique Solutions

Techsol Developing Innovative Software Solutions and Technology Expertise for Pharma

ARTICLE

32

The pharmaceutical sector finally gets the recognition it deserved

32

What is Coronavirus?

™

™

™

™

11 | MARCH 2021

12 | MARCH 2021

™

™

13 | MARCH 2021

Debasish Bhattacharya Director

Scube Scientic Software Solutions Pvt. Ltd. Innovative and Affordable Scientic Software Solutions

16 | MARCH 2021

™

G

lobalization has brought the world closer, and the use of IT, the development in many sectors has made the operations easy and effective. The scientific advances depend on the ideas, conceptual leaps and the paradigm shifts. The fast evolving nature of these industries has urged the necessity of software solutions in different arenas of the industry.

By carefully examining the situation, Debasish Bhattacharya thought of entering into this vertical of software development. Scube Scientific is a company that provides affordable and innovative scientific software solutions.

The CompanyStarted in the year 2004, Scube Scientific is an ISO 9001:2015 certified renowned distributor of some of the leading edge, easy to use and affordable scientific software tools pan India and also to the neighbouring SAARC countries. Their services cater for assisting the research scientists with tools that help them in their daily scientific activities.

Their marketing and technical-support team work together with the clients to offer tailor-made solutions for their scientific software needs. Their operational excellence is derived from the responsiveness and over a decade of experience working on a wide range of software, platforms and technologies.

Scube Scientific is one of the most reputed and highly practised companies that promises an unmatched expertise in the fields of Computational Chemistry, Biology, Mathematical Modeling, Statistical Analysis, Data Mining and Market Research. With their outstanding and innovative services, the company has collaborated with some of the most renowned companies of the world like Gaussian Inc., Wolfram Research Inc., and PerkinElmer Informatics, to name a few.

The Initial Challenges and How Scube TriumphedInitially, the company's major challenge came from the unawareness of people about the utility of computer software in scientific research. So it took them quite a long time to convince professors and scientists of the utility and functionality of the software.

The issue was simple. They did not feel the need to push their sales, but what they basically did was talk to the actual user and try and understand their need and align the product based on that need.

“We believe that some of the company's core factors have really contributed to a great deal in leading our organization on the path to success.”

™

These includeŸ Ÿ Ÿ Ÿ Ÿ

Dedicated manpower Trying to offer proper service to our clients As a solution provider approach Right product offering Very adaptive in approach

The Products and ServicesScube Scientific offers a wide range of products and services to its clientele. The innovation in their services has helped research scientists carry out their tasks effectively.

The company has pursued a long-term vision to provide integrated portfolio of software and services to scientific research institutes, academia, industry and the Government. Its dedication and expertise has earned an array of distinguished clients such as DRDO, CSIR Labs, and every major IIT and University. In addition to that, its experienced team of Application Specialists brings together knowledge and domain expertise to provide you streamlined solutions in the fields of Computational Chemistry, Computational Biology, Mathematical Modeling, Statistical Analysis, Data Mining and Market Research.

What the Clients Think“I thank Scube for its very good follow up to get SCIGRESS and ADMEWORKS ModelBuilder installed. I am happy with your reciprocation towards your customers.

I assure to improve the business with you by procuring softwares from you.” - Dr. Kajal Chakraborty, Central Marine Fisheries Research Institute.

“We appreciate the service provided by Scube Scientific software solutions during the complete process of Gaussian TCP Linda purchase and implementation. Scube Team has good knowledge about Gaussian &GaussView packages as well as excellent skills in Linux platform. We wish them the best for their future.” - Prof. Arup Banerjee, Theory and simulation Lab, Raja Ramanna Centre for Advanced Technology Indore.

“Wolfram trainers delivered lectures on Wolfram Mathematica during the “Short term course on software tools for scientific research: Mathematica and LateX” organised by department of Mathematics and Mechanical Engineering, MNIT Jaipur. We appreciate Scube effort in the successful completion of the event.” - Dr. Rashmi Jain, Department of Mathematics and Mechanical Engineering, MNIT Jaipur.

17 | MARCH 2021

Know the Leader Debasish Bhattacharya Leading the Way Mr. Debasish Bhattacharya, who has over 20 years of experience in IT sales, started this business in the year 2004. During that time, idea about IT only enclosed office automation but no IT initiative on scientific research. Hence, Mr. Debasish thought of creating a business which can help research scientists with appropriate tools that will help them in their daily scientific research activities.

18 | MARCH 2021

™

John Jackson CEO

INTERNATIONAL HEALTH MANAGEMENT ASSOCIATES Redening the Drug Discovery Process with Unique Solutions

20 | MARCH 2021

™

I

t's a charismatic century where the world is changing its way by adopting and adapting to the technological disruptions. Numerous scientific developments and innovations take place throughout industries including pharmaceutical and healthcare industries every single day improving human health and forwarding life-expectancy one step further. However, the cost of drug-development or discovery processes continues to rise and the chances of success continue to plummet. According to McKinsey, every year, the top 20 pharmaceutical companies spend approximately $60 billion on the research and development of drug discovery.

The drug discovery process consists of steps of identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy.

Antibiotic resistance is on the rise. The healthcare industry is now in need of new antibiotics and therapies to treat infectious diseases and viruses. This is where prestigious companies like International Health Management Associates or IHMA enter. The company is working with pharmaceutical companies to develop new antibiotics and therapies for infectious diseases. They are also working with diagnostic companies in order to test these new antibiotics.

The Leading Light of IHMA Jack Johnson, the CEO of IHMA, has years of experience in the pharmaceutical industry such as Pfizer, Beecham Laboratories and G.D. Searle. He founded the company in 1992 with an aim to help the pharmaceutical companies to meet the challenges prevailing in the drug development industry. During the 18-years of experience in the pharmaceutical industry, he launched products named cefoperazone, amoxicillin/clavulanic acid, ticarcillin/clavulanic acid, mupirocin and lomefloxacin respectively.

This is the efforts of Jackson, IHMA has become one of the world's leading providers of antimicrobial drug development support. The company offers complete collaboration and flexibility with all of their clients around the world ensuring ongoing development success.

As the leading global microbiology service provider to the biopharmaceutical industry, IHMA's mission is to utilize their widespread laboratory and industry expertise to support efficient and effective anti-infective product development.

™

Outstanding Products and Services Full service microbiology and molecular laboratories are the most distinguishing services of IHMA. It is a leading benefactor of antimicrobial drug development studies that offers an all-inclusive domain proficiency in all stages of antimicrobial drug development. The phases of antimicrobial drug development include: drug discovery, clinical development, regulatory approval and commercialization. With branches in the USA, Europe, India, and China, IHMA collaborates with companies around the world in the pharmaceutical, biotechnology and diagnostic device industry.

The clients of the company include those organizations who need: 1.Pre-clinical studies including in vitro and pharmacodynamic studies Ÿ Ÿ Ÿ

MIC Profile Time Kill Resistance Development

2.Global support of all phases of clinical trials Ÿ Ÿ

Therapeutics Diagnostic Devices

3.Antimicrobial resistance (AMR) surveillance Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ

Bacterial Fungal Molecular Characterization of AMR Support with New Therapeutic Approaches Bacteriophage WGS Diagnostics

The Phases and Expertise of IHMA in Antimicrobial Drug Development As mentioned earlier, IHMA supports all phases of antimicrobial drug development, from discovery to commercialization.

IHMA reserves incomparable expertise in the spheres of microbiology, pharmaceutical, medical, and diagnostic.

This highly elevated skill set ensures effortless success for the phases of drug development, clinical trial support, regulatory approval and commercialization.

21 | MARCH 2021

Drug Discovery: The process of discovering new anti-infective entirely depends upon the well-timed generation of relevant and informative data. The full suite of technical competences, resources, and domain expertise of IHMA employees are enough to support the discovery needs of the clients in a collaborative and flexible manner.

The timing of educating the global clinical and scientific community about the new product's attributes, and the ability of local clinical microbiology laboratories to test the product against the organisms they encounter in their clinical settings are considered as the main attributes for a successful commercialization. IHMA offers a number of solutions uniquely suited to be used in a collaborative and successful manner to help develop a successful plan for commercialization.

The proficiencies in the drug discovery include: Areas of Expertise Ÿ Ÿ Ÿ

Bacterial Repository Specialized Microbiology Laboratory Services Clinical Scientific Expertise

“We are always evaluating cutting-edge technologies and novel study designs to support changing infectious disease field”

Antimicrobial Resistance Surveillance Clinical Scientific Expertise Manufacturers Interface and Performance Program (MIPP) Ÿ Antimicrobial Voluntary Evaluation Program (AVEP) Ÿ Surveillance Data Link Network (SDLN) Ÿ Specialized Microbiology Laboratory Services Ÿ Ÿ Ÿ

Clinical Development Among the many challenges in the way of designing a clinical product, economic constraints, uncertain regulatory landscapes, and the continuous evolution of unique strategies for the prevention and treatment of infectious diseases are significant.

The technical competencies in clinical development include: Ÿ Ÿ Ÿ

Central Laboratory Microbiology Services Specialized Microbiology Laboratory Services Clinical Scientific Expertise

Regulatory Submission A successful regulatory outcome depends on many factors including scientifically and clinically sound data, presented in a concise and coherent manner. From the microbiology perspective, the expert team of IMHA ensures that these goals are met with their proficiency in the domain.

Expertise in Regulatory submission include: Ÿ Ÿ Ÿ Ÿ

Central Laboratory Microbiology Services Antimicrobial Resistance Surveillance Specialized Microbiology Laboratory Services Clinical Scientific Expertise

Contribution of IHMA to the Development of the Industry IHMA is a premier provider of antimicrobial drug development studies. With laboratories in both the US and Europe, the company partners with clients around the world in the biotechnology, pharmaceutical, and diagnostic fields. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, creating key milestones along–the continuum from drug development to commercialization. The company also utilizes state-of-the-art technology, which enables the team in first-class testing and data as well as sound economic frameworks. The services offered by IHMA are customizable to best align with the unique testing needs of the clients. This ensures successful drug development, commercialization, and post-marketing pathways.

While asked about what the future holds for the company, John Jackson, the CEO, asserted, “We are always evaluating new technologies and new study designs to support the changing infectious disease therapy field. For example, the use of technology such as MALDI-TOF and whole genome sequencing is shifting from experimental technology to standard laboratory procedures.”

Commercialization

22 | MARCH 2021

™

Satya S S Sagi founder and CEO

TECHSOL Developing Innovative Software Solutions and Technology Expertise for Pharma

24 | MARCH 2021

™

I

ntroduction and Background of the company

Techsol Corporation was founded in 2010 under the leadership of Satya S S Sagi, CEO with his vision for offering value-based technology services and developing innovative software solutions for pharma. With over 20 years of life sciences industry experience, the humble beginnings of Techsol was started by him in a small penthouse overseeing Hi-Tec city in Hyderabad, India.

Today with our headquarters in Princeton, NJ, we are recognized as a valuable tech partner for several global clients with an expanded team of 140+ subject matter experts.

With over 10+ years of industry experience, we have learnt that keeping up a commitment and winning the trust of clients comes only with diligence, integrity, transparency, and continuous pursuit of excellence. In short these have been our ingredients to develop a sustainable innovation mindset regardless of shortcomings. Above all, we have developed the virtue of being agile to adapt, evolve and align ourselves constantly with our client's business goals.

We provide business-value to our clients by delivering high-quality configurable solutions & specialized services with the focus on quality and regulatory compliance. Our core domain expertise was developed using our committed domain experts through constant industry interactions, and by adopting industry best practices. For eg: All validation services we provide are in alignment to the GAMP5 riskbased validation framework. Our Service Desk operations are run by using the principles of ITIL and we deliver projects using the PmBOK methodology.

We currently focus on providing technology and technology enabled data services to address some of the specific challenges of Pharma in the R&D, Medical Affairs and Commercial processes. In the Clinical Development and Pharmacovigilance, we offer system integrations services and Managed cloud services (Accel Solutions) in partnership with Oracle Health Sciences. We are also actively developing a PVSentinel platform that addresses some of the operational challenges of Pharmacovigilance by utilizing AI/ Automation and digital approaches.

In the Medical Affairs domain, we began developing “MedInquirer” about 4 years ago and this was our first cloud solution just for medical communications. Today, we

™

have broadened our innovation landscape by launching SciMax Global (www.scimaxglobal.com) which is a patient-centric Outcomes & Evidence driven global medical affairs platform.

Our commitment to introduce high-end technology through SciMax for Medical Affairs will be a game changer for Pharma & Service providers. We will be the first company to provide such a comprehensive collaborative platform for multi-functional stakeholders.

As we look more closely, we know for a fact that this adaptive change requires synergy with other business systems. Hence, we have dedicated ourselves to building configurable technology solutions which can easily support cross-platform integrations.

Joe Pierce, CEO, SciMax Global says, “I've been in the industry for nearly 25 years and Techsol's SciMax is simply the best Medical Affairs solution available. We are extremely excited to continue to enhance, develop, implement, and support for end to end management of Medical Affairs Business Challenges associated with offering Technology driven services to Pharma Keeping up to speed with rapid advancements in technology requires a considerable amount of dedication to reduce talent development time. Understanding the challenge and offering the right solution for clients with changing tech requirements is a key specialty for us because we have learned to thrive with agility.

With all the market entry barriers, timing is an essential component of innovation success. Its primarily for that reason, we have established synergetic relationships with our clients and partners to derive value from their knowledge and to offer our technology expertise. Another important success factor that we were able to leverage successfully is our tactical capability to reuse technical and knowledge assets to solve problems more effectively.

With our pharma industry domain expertise & strong technology experience, we have proven capabilities to: Ÿ

Build & deliver configurable, process-oriented digital platforms for pharma

Ÿ

Provide lean and integrated cloud solutions

Ÿ

Offer actionable intelligence with advanced data analytics

25 | MARCH 2021

Ÿ

Transform business processes with incremental innovation

“Our vision is to become a pioneer in providing valuedriven, high quality, process-oriented technology services and simplified business solutions for the pharmaceutical industry,” says Satya S S Sagi, founder and CEO of Techsol Working with Strategic customers We have been providing unparalleled technical and functional consulting guidance across the clinical development, drug safety and medical affairs verticals with strategic business partnerships. We had the opportunity of implementing and rolling out SciMax Platform for both a multi-national rare disease pharma and a global Med Info Contact Center. Both our clients were looking out for a purpose-built configurable solution that can be tailored and scaled up as their business needs grow. The multi-channel intake, cross-platform integrations, robust case management workflows, built-in reporting & analytics has given them considerable advantage to automate manual tasks and have one single comprehensive solution for all their medical communication needs.

In return, their knowledge capital has been extremely valuable in further strengthening the product's competence.

With two major version releases, today we can claim that SciMax is one of the most advanced cloud solutions in the industry. And we haven't stopped here because we are already working on the next big wave in infusing artificial intelligence capabilities.

New Capabilities We are actively working towards announcing the launch of multiple new products and services during this year. Our appetite for innovation has increased with our domain knowledge. Major announcement is the launch of “PVSentinel” cloud solution for pharmacovigilance operations oversight and compliance governance.

PVSentinel is a process orchestration and compliance governance solution to streamline, track and report the outcomes of PV operations and cross-functional activities managed by different vendors, partners and affiliates.

We are also working on expanding our service lines to address tech and tech enabled data service capabilities across compliance and quality processes of R&D, Medical and Commercial. We are working towards launching new tech verticals such as Quality, Manufacturing/ Supply,

26 | MARCH 2021

Patient Engagement etc. and new horizontal services such as tech enabled Pharmacovigilance data services.

Work Culture and Team First and foremost, Techsol's work culture is fabricated with each team members commitment towards positive outcomes in anything we do. The close-knit collaboration amongst our team members has been visibly recognized by all our clients and that has encouraged our enthusiasm to provide high-quality services all these years. As part of our corporate responsibility, we have established an amicable work environment with open-door policy, talent recognition, continuous learning support and celebrating our success together.

Our talent pool is constantly nourished with continuous knowledge capital, autonomous work ownership, festival get-togethers, social cause shouldering, individual and team empowerment. All these elements positively influence our team to bridge with clients, understand their business goals and work towards common success.

“Our vision is to become a pioneer in providing valuedriven, high quality, process-oriented technology services and simplified business solutions for the pharmaceutical industry,” ™

The executive leadership from behind the scenes have been instrumental to ensure that all team members get the best of every client interaction as it an opportunity for them to contribute with their competence and increase the value of the entire business relationship.

We provide growth enabling a competitive environment, invest our resources to foster and develop their growth as leaders. Our leadership team that includes engineers, client specialists, sales gurus, scientists, and entrepreneurs, leverage their collective wisdom and capabilities cohesively to create and deliver organization wide focus on client delight. Techsol' dedicated team works across its two global offices in Princeton (NJ), Hyderabad (India) and Seoul (South Korea) to support our global clientele. Our consistent success in delivering client delight is due to seamless harmony and teamwork between our staff, leadership and board.

believe and accept what AI is perceived to do as to what it really can do.

The fruitful outcomes of AI pilot projects are claiming that it can be a boon for winding down redundant costly processes. Perhaps, it's true that continuously trained intelligent algorithms can prove their benefit without doubt. But is the industry willing to put AI to work especially for making critical healthcare decisions or for discovering new paths of disease treatment? Perhaps we will get there soon enough to know it for real.

Key strengths of Techsol: Ÿ

Specialized, innovative, software solutions and services company serving Global Pharmaceutical, Life sciences, and Healthcare companies in three verticals – Medical Affairs, Drug Safety and Clinical Development

Entrepreneur Challenges in the space

Ÿ

The learning curve for mastering tech solutions is pretty steep especially in the pharma industry because of stakeholder variances, cross-functional processes, compliance obligations and the vastness of the tech ecosystem. Today company mergers and acquisitions have increased in multiple folds, therefore there is very little margin to win or lose an opportunity.

Strong presence and leadership position in the fast growing Asia Pacific pharma market. Fast growing company in North America market. New entrant in EU and middle east

Ÿ

Strong promoters and leadership team with committed involvement in company growth over the past 9 years

Ÿ

Matured, audit ready Quality Management System with relevant certifications, standards, data privacy & protection

Ÿ

Most preferred strategic partner for Oracle health sciences, world's largest pharma focused enterprise software company. Very strong techno functional system integration skills on world's leading drug safety database – Argus Safety

Ÿ

More than 50 Satisfied and Referenceable pharma customer base across solution areas

Ÿ

Established, regulatory compliant GxP cloud designed for emerging pharma companies

For anyone who has dreamed to take the path of Pharma tech entrepreneurship, having the right sense of timing is critical to launch an innovation in a heavily crowded tech market. For new service providers, having the right partnership model is crucial to go against market barriers.

Understanding current market trends, innovation landscape, staying updated on regional regulations, observing the pace of technology adoption and gaining competitive intelligence is of paramount importance to win against the odds. The challenge for any new tech innovation in this arena will continue to revolve around quality, compliance and risk. Another key element is to develop and offer solutions that will continue to scale and grow for your clients over the years.

AI and Next Generation Tech Adoption by Pharma With the advent of Artificial Intelligence use in many other industries, pharma is preparing its aptitude to gradually adopt it for next generation healthcare. Like any new technology, there is also a great amount of scepticism to

™

27 | MARCH 2021

THE PHARMACEUTICAL SECTOR FINALLY GETS THE RECOGNITION IT DESERVED

30 | MARCH 2021

™

A

lthough the ongoing COVID-19 pandemic has significantly impacted several sectors across the world, it comes as a silver lining for the pandemic pharmaceutical sector. In the last few months, Pharma companies across the world have had a good run across the world. It has managed to become the most preferred stock amongst various portfolio managers, as stock markets recording all-time high across almost all nations. This growth may seem overhyped to a lot of people due to the covid scenario, but experts beg to differ. According to them, pharma is finally representing its genuine valuation in the market.

However, here comes a question, how can an essential sector like pharma be undervalued for such a long time? Well, a short answer here would be stringent regulatory norms. To simply put, it was challenging for pharmaceutical companies to cope up with the regulatory standards. For the past decade, these pharmaceuticals have found

™

themselves under heavy scrutiny from agencies like the U.S FDA, with some even receiving frequent warning letters every now and then.

But with the pandemic in full throttle, the businesses seem to have returned in huge lots as regulators decide to levy numerous rules. This has encouraged U.S enterprises to partner with manufacturers worldwide to tap major market share during these challenging times.

Optimism in pharma is at an alltime high. We can see the evidence of this in global stock markets. However, experts are still uncertain about their longterm trajectory. A crucial element that concerns the future of this sector is the FDA's stance after the lockdown ends. If regulations go back to remain stringent for companies then the businesses are surely expected to slowly evaporate as earlier.

31 | MARCH 2021

WHAT IS

CORONAVIRUS?

34 | MARCH 2021

™

T

he Coronavirus is a group of all the infections that can cause numerous scopes of illnesses in people.

Sicknesses like the basic cold and progressively extreme structures like SARS and MERS are dangerous.

HIGHLIGHTS Ÿ India is not fully prepared to

cope with the mysterious coronavirus. Ÿ Three suspected cases of the

coronavirus were reported in the Delhi today Ÿ Death toll crosses almost 130

in China, India steps ups its preparations to tackle the crisis The WHO (World Health Organization) in its most recent report on Coronavirus circumstance said that there was a high danger of the infection in all over China and high at the territorial and worldwide levels.

Coronavirus began in China's Wuhan region, the fatal Coronavirus has now spread to over twelve major nations including the United States, ™

Japan, India and South Korea.

The majority of the significant International air terminals in India are on high caution and are screening all the travelers originating from China and different nations. Numerous individuals are held under perception for this associated case with coronavirus in various urban communities of India, for example, Hyderabad, Mumbai and New Delhi.

The patients who had returned once again from China as of late, were admitted to the RML Hospital (Dr Ram Manohar Lohia) in New Delhi with comparable respiratory manifestations to those of the dangerous ailment at present grasping the world.

This infection has spread to each edge of the world with right around 19 nations, including India's neighbors Sri Lanka and Nepal. At last, the infection can possibly spread quickly to different nations due to its propensity to spread human-to-human transmission, as per the World Health Organization.

35 | MARCH 2021

TBF team is extremely approachable and efficient. I am very impressed by their professional attitude and the readiness to improve.

Gautam Chaturvedi | Founder & MD | Pine Tree Pictures

“Thank you The Business Fame Magazine for featuring us in your COVID-19 edition. We wish you all the very best in your endeavors ahead” Dr. Sanjay Arora | Managing Director Suburban Diagnostics India Pvt. Ltd.

I found The Business Fame Magazine team very professional. Am quite happy to deal with them, the write up editing and quality is very good.

Koheli Puri | Founder & MD | Studio XP